HHS on Tues­day un­veiled its long-await­ed Make Amer­i­ca Healthy Again strat­e­gy re­port, in­clud­ing plans for changes to the child­hood vac­cine sched­ule, stricter over­sight of how drugs are ad­ver­tised to pa­tients, and ap­proach­es that could speed some new drug de­vel­op­ment.

The new re­port, which builds off of an ear­li­er one from May, is still light on de­tails about vac­cine-re­lat­ed changes. It says the White House Do­mes­tic Pol­i­cy Coun­cil and HHS will de­vel­op a new vac­cine frame­work to en­sure the US "has the best child­hood vac­cine sched­ule" and will be "mod­ern­iz­ing Amer­i­can vac­cines with trans­par­ent, gold-stan­dard sci­ence" while "en­sur­ing sci­en­tif­ic and med­ical free­dom."

It al­so em­braces the skep­ti­cism that HHS Sec­re­tary Robert F. Kennedy Jr. has for many vac­cines, which HHS and oth­er health agen­cies have trans­formed in­to ac­tion through pol­i­cy changes and re­plac­ing many gov­ern­ment lead­ers, ad­vi­sors and ex­perts.

Lund­beck will part­ner out its com­mer­cial med­i­cines in 27 mar­kets by the end of this year, the brain health drug­mak­er said Tues­day.

The Dan­ish bio­phar­ma is hand­ing off mar­ket­ing re­spon­si­bil­i­ties to three com­pa­nies — Swixx Group, Zuel­lig Phar­ma and New­Bridge Phar­ma­ceu­ti­cals — in cer­tain ar­eas of Asia, Eu­rope, South Amer­i­ca, North Africa and the Mid­dle East. Lund­beck will keep sup­ply­ing and man­u­fac­tur­ing the drugs un­der the part­ner­ships.

The 27 mar­kets made up about 12% of Lund­beck’s sales in 2024, the com­pa­ny said. Lund­beck makes psy­chi­atric treat­ments like Rex­ul­ti and neu­ro­log­i­cal dis­or­der drugs like the mi­graine med­i­cine Vyep­ti.

Lund­beck will con­tin­ue mar­ket­ing its med­i­cines in near­ly two dozen mar­kets where it makes near­ly 90% of its sales, in­clud­ing the US, UK, Chi­na, Brazil, Japan, Ger­many and its home coun­try of Den­mark, among oth­ers.

SAN DIEGO -- Thir­ty min­utes in­to a speech ex­tolling the achieve­ments of ge­nom­ic med­i­cine, Er­ic Green ad­dressed what he called the “ele­phant in the room": his forced de­par­ture as an NIH di­rec­tor.

For 16 years, Green led the Na­tion­al Hu­man Genome Re­search In­sti­tute that works to help di­ag­nose and treat ge­net­ic dis­ease in a wider set of the pop­u­la­tion. In March, the Trump ad­min­is­tra­tion de­clined to re­new his five-year term.

“Let's just say that they de­cid­ed that it was just too easy just not to re­new me, even though I was set to be reap­point­ed, be­cause that would be an easy way to de­cap­i­tate one of the lead­ers,” Green told a crowd Mon­day at the Ad­vances in Genome Bi­ol­o­gy and Tech­nol­o­gy’s pre­ci­sion health meet­ing in San Diego.